United States and European Multicenter Prospective Study for the Analytical Performance and Clinical Validation of a Novel Sensitive Fully Automated Immunoassay for Calcitonin
- PMID: 28687633
- DOI: 10.1373/clinchem.2016.270009
United States and European Multicenter Prospective Study for the Analytical Performance and Clinical Validation of a Novel Sensitive Fully Automated Immunoassay for Calcitonin
Abstract
Background: The objective of this study is the validation and proof of clinical relevance of a novel electrochemiluminescence immunoassay (ECLIA) for the determination of serum calcitonin (CT) in patients with medullary thyroid carcinoma (MTC) and in different diseases of the thyroid and of calcium homeostasis.
Methods: This was a multicenter prospective study on basal serum CT concentrations performed in 9 US and European referral institutions. In addition, stimulated CT concentrations were measured in 50 healthy volunteers after intravenous calcium administration (2.5 mg/kg bodyweight).
Results: In total, 1929 patients and healthy controls were included. Limits of blank, detection, and quantification for the ECLIA were 0.3, 0.5, and 1 ng/L, respectively. Highest intra- and interassay coefficients of variation were 7.4% (CT concentration, 0.8 ng/L) and 7.0% (1.1 ng/L), respectively. Medians (interval) of serum CT concentrations in 783 healthy controls were 0.8 ng/L (<0.5-12.7) and 3 ng/L (<0.5-18) for females and males, respectively (97.5th percentile, 6.8 and 11.6 ng/L, respectively). Diagnostic sensitivity and specificity were 100%/97.1% and 96.2%/96.4%, for female/males, respectively. Patients (male/female) with primary hyperparathyroidism, renal failure, and neuroendocrine tumors showed CT concentrations >97.5th percentile in 33%/4.7%, 18.5%/10%, and 8.3%/12%, females/males, respectively. Peak serum CT concentrations were reached 2 min after calcium administration (161.7 and 111.8 ng/L in males and females, respectively; P < 0.001).
Conclusions: Excellent analytical performance, low interindividual variability, and low impact of confounders for increased CT concentrations in non-MTC patients indicate that the investigated assay has appropriate clinical utility. Calcium-stimulated CT results suggest good test applicability owing to low interindividual variability.
© 2017 American Association for Clinical Chemistry.
Similar articles
-
Reference values of serum calcitonin with calcium stimulation tests by electrochemiluminescence immunoassay before/after total thyroidectomy in Japanese patients with thyroid diseases other than medullary thyroid carcinoma.Endocr J. 2016 Jul 30;63(7):627-32. doi: 10.1507/endocrj.EJ16-0107. Epub 2016 Apr 20. Endocr J. 2016. PMID: 27097651
-
Serum calcitonin reference values for calcium stimulation tests by electrochemiluminescence immunoassay in Japanese men with non-medullary thyroid carcinoma.Surg Today. 2018 Feb;48(2):223-228. doi: 10.1007/s00595-017-1578-7. Epub 2017 Aug 18. Surg Today. 2018. PMID: 28821980
-
Calcitonin levels by ECLIA correlate well with RIA values in higher range but are affected by sex, TgAb, and renal function in lower range.Endocr J. 2020 Jul 28;67(7):759-770. doi: 10.1507/endocrj.EJ19-0610. Epub 2020 Apr 8. Endocr J. 2020. PMID: 32269183
-
Calcitonin measurement and immunoassay interference: a case report and literature review.Clin Chem Lab Med. 2016 Dec 1;54(12):1861-1870. doi: 10.1515/cclm-2015-1161. Clin Chem Lab Med. 2016. PMID: 27166721 Review.
-
Calcitonin as Biomarker for the Medullary Thyroid Carcinoma.Recent Results Cancer Res. 2015;204:117-37. doi: 10.1007/978-3-319-22542-5_5. Recent Results Cancer Res. 2015. PMID: 26494386 Review.
Cited by
-
[Functional diagnostics in endocrinology].Internist (Berl). 2018 Jan;59(1):38-47. doi: 10.1007/s00108-017-0360-7. Internist (Berl). 2018. PMID: 29260252 Review. German.
-
Circulating Biomarkers in Medullary Thyroid Carcinoma: Bridging Laboratory Complexities and Clinical Application Through Algorithm Design.J Clin Med. 2025 Aug 9;14(16):5645. doi: 10.3390/jcm14165645. J Clin Med. 2025. PMID: 40869471 Free PMC article. Review.
-
Medullary thyroid carcinoma: recent advances in identification, treatment, and prognosis.Ther Adv Endocrinol Metab. 2021 Oct 8;12:20420188211049611. doi: 10.1177/20420188211049611. eCollection 2021. Ther Adv Endocrinol Metab. 2021. PMID: 34659736 Free PMC article. Review.
-
Update on Multiple Endocrine Neoplasia Type 2: Focus on Medullary Thyroid Carcinoma.J Endocr Soc. 2018 Jul 13;2(8):933-943. doi: 10.1210/js.2018-00178. eCollection 2018 Aug 1. J Endocr Soc. 2018. PMID: 30087948 Free PMC article. Review.
-
RET Y791F in MEN2: a variant presumed non-pathogenic, yet lacking conclusive evidence of insignificance.Gland Surg. 2025 Jun 30;14(6):1033-1041. doi: 10.21037/gs-2025-130. Epub 2025 Jun 26. Gland Surg. 2025. PMID: 40671763 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous